Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prior Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7,058 result(s) found for: Prior Placebo. Displaying page 284 of 353.
    «« First « Previous 280  281  282  283  284  285  286  287  288  Next» Last»»
    EudraCT Number: 2009-013538-26 Sponsor Protocol Number: 20080615 Start Date*: 2010-04-07
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 853 in Subjects with Inadequately Controlled Asthma
    Medical condition: Inadequately Controlled Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-006946-24 Sponsor Protocol Number: NV25025 Start Date*: 2009-12-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high...
    Medical condition: High grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049701 Cervical intraepithelial neoplasia II LLT
    9.1 10049702 Cervical intraepithelial neoplasia III LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) BE (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2019-004789-17 Sponsor Protocol Number: RD.06.SPR.203065 Start Date*: 2020-07-08
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004303-19 Sponsor Protocol Number: BSX - 001 Start Date*: 2007-04-25
    Sponsor Name:Cerimon Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulc...
    Medical condition: Steroid-refractory ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009900 Colitis ulcerative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) CZ (Prematurely Ended) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001825-15 Sponsor Protocol Number: A3921192 Start Date*: 2017-02-16
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULA...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed) BE (Completed) DE (Completed) GB (Completed) PL (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000284-32 Sponsor Protocol Number: SHP634-401 Start Date*: 2018-02-05
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinan...
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051315 Congenital hypoparathyroidism PT
    20.0 10014698 - Endocrine disorders 10075900 Primary hypoparathyroidism PT
    20.0 10014698 - Endocrine disorders 10021041 Hypoparathyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) SE (Completed) DK (Completed) ES (Completed) NO (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006498-49 Sponsor Protocol Number: 21103 Start Date*: 2022-08-18
    Sponsor Name:ACELYRIN, Inc.
    Full Title: A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis
    Medical condition: Non-infectious, Intermediate-, Posterior- or Pan-uveitis
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004853 10022557 Intermediate uveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    20.0 100000004853 10033687 Panuveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003780-38 Sponsor Protocol Number: P05575 Start Date*: 2009-10-27
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A 2-Year, Dose Range-Finding, Adaptive-Design Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) CZ (Prematurely Ended) SK (Completed) GR (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001637-18 Sponsor Protocol Number: CKI- 302 Start Date*: 2006-11-13
    Sponsor Name:NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)
    Full Title: A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart f...
    Medical condition: Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) CZ (Completed) BE (Completed) DK (Prematurely Ended) GB (Completed) HU (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023186-21 Sponsor Protocol Number: MOT114479 Start Date*: 2011-06-28
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist ...
    Medical condition: Diabetic gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004754-33 Sponsor Protocol Number: 109RA201 Start Date*: 2009-01-29
    Sponsor Name:Biogen Idec Limited
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of BG00012 when given with Methotrexate to Subjects with Active Rheuma...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-003142-32 Sponsor Protocol Number: TBR-760-NFPA-201 Start Date*: 2020-07-16
    Sponsor Name:Tiburio Therapeutics, Inc.
    Full Title: A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients with Non-Functioning Pituitary Adenomas
    Medical condition: Non-Functioning Pituitary Adenomas
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10035079 Pituitary adenoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000671-16 Sponsor Protocol Number: BC28027 Start Date*: 2013-02-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities
    Medical condition: - Stable Cardiovascular Disease and - Diabetes Mellitus Type 2 or Pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    14.1 10027433 - Metabolism and nutrition disorders 10036481 Pre-diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) AT (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000959-40 Sponsor Protocol Number: PCI-32765DBL3001 Start Date*: 2013-08-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vi...
    Medical condition: Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) CZ (Completed) DE (Completed) BE (Completed) HU (Completed) ES (Prematurely Ended) FI (Completed) IT (Prematurely Ended) DK (Completed) PL (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-002090-31 Sponsor Protocol Number: CAT-354-0603 Start Date*: 2007-09-26
    Sponsor Name:MedImmune Limited
    Full Title: A double-blind, placebo-controlled parallel-group study to assess the efficacy, safety, and tolerability of CAT-354
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004438-32 Sponsor Protocol Number: MOT115816 Start Date*: 2012-04-25
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s...
    Medical condition: Investigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003400-20 Sponsor Protocol Number: M11-313 Start Date*: 2012-04-12
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-002193-40 Sponsor Protocol Number: DT-001-R-004 Start Date*: 2018-04-04
    Sponsor Name:Afyx Therapeutics A/S
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Study to Assess the Safety and Efficacy of Three Doses of Clobetasol Propionate when Administered Intra-orally Twice Daily in...
    Medical condition: Oral Lichen Planus (OLP). OLP is a common, chronic mucosal disease associated with a cell-mediated immunological dysfunction and characterized by exacerbations of inflammation, which can lead to ul...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10030983 Oral lichen planus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001057-21 Sponsor Protocol Number: PO3672 Start Date*: 2005-12-16
    Sponsor Name:Schering-Plough Research Insititute, a division of Schering Corporation
    Full Title: Vicriviroc in Combination Treatment with Optimized ART Regimen in Experienced Subjects (VICTOR-E1)
    Medical condition: HIV infection (R5-tropism only) with previous therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10200172 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000347-14 Sponsor Protocol Number: D6160C00028 Start Date*: 2004-09-10
    Sponsor Name:AstraZeneca Sverige
    Full Title: A 52-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered...
    Medical condition: Men or women who are >18 years of age or older at the enrolment visit (visit 1) diagnosed with type 2 diabetes and treated with diet alone or on treatment with a single oral anti diabetic agent or ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) HU (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 280  281  282  283  284  285  286  287  288  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 09:52:29 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA